EPISODE · Apr 9, 2024 · 55 MIN
Dr. Doron Behar, MD, PhD - Founder & CEO, Igentify - Making Medical Genomics More Accessible And Actionable
from Progress, Potential, and Possibilities Podcast / Show · host Ira Pastor / Dr. Doron Behar
Send us Fan MailDr. Doron Behar, MD, PhD is Founder & CEO of an end-to-end genetic platform company, Igentify ( https://www.igentify.com/ ), that provides a suite of digital tools designed to scale the provision of genomic medical services to more people worldwide, making it more accessible and actionable for clinicians, laboratories, and patients. Dr. Behar received his degrees from the Technion - Israel Institute of Technology. As an MD, he has dual specialization in Internal Medicine and Critical Care Medicine from Rambam Medical Center in Haifa, Israel. Dr. Behar's research areas of interest are across the broad range of evolutionary genomics, ancestry, phylogenetics, and translational genomics. He has been the leading author and co-author of numerous research papers in these areas. Dr. Behar is the former Chief Scientific Officer of Gene-by-Gene Ltd., a commercial genetic testing company. His expertise covers various aspects of mass genotyping, including regulation, privacy, genetic analysis, quality assurance, and more. Support the show
What this episode covers
Send us Fan Mail Dr. Doron Behar, MD, PhD is Founder & CEO of an end-to-end genetic platform company, Igentify ( https://www.igentify.com/ ), that provides a suite of digital tools designed to scale the provision of genomic medical services to more people worldwide, making it more accessible and actionable for clinicians, laboratories, and patients. Dr. Behar received his degrees from the Technion - Israel Institute of Technology. As an MD, he has dual specialization in Internal Medicine ...
NOW PLAYING
Dr. Doron Behar, MD, PhD - Founder & CEO, Igentify - Making Medical Genomics More Accessible And Actionable
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m